By a News Reporter-Staff News Editor at Hematology Week -- Current study results on Lymphoproliferative Disorders have been published. According to news reporting out of Amsterdam, Netherlands, by NewsRx editors, research stated, "Caloric restriction (CR) is proposed to decrease tumorigenesis through a variety of mechanisms including effects on glycolysis. However, the understanding of how CR affects the response to cancer therapy is still rudimentary."
Our news journalists obtained a quote from the research from Netherlands Cancer Institute, "Here, using the E mu-Myc transgenic mouse model of B-cell lymphoma, we report that by reducing protein translation, CR can reduce expression of the prosurvival Bcl-2 family member Mcl-1 and sensitize lymphomas to ABT-737-induced death in vivo. By using E mu-Myc lymphoma cells lacking p53, we showed that CR mimetics such as 2-deoxyglucose led to a decrease in Mcl-1 expression and sensitized lymphoma cells to ABT-737-induced death independently of p53. In keeping with this, E mu-Myc lymphoma cells lacking the BH3-only proapoptotic members Noxa, Puma, or Bim were also sensitized by CR mimetics to ABT-737-induced death. Remarkably, neither the loss of both Puma and Noxa, the loss of both Puma and Bim, nor the loss of all three BH3-only proteins prevented sensitization to ABT-737 induced by CR mimetics. Thus, CR can influence Mcl-1 expression and sensitize cells to BH3 mimetic-induced apoptosis, independently of the main BH3-only proteins and of p53."
According to the news editors, the research concluded: "Exploiting this may improve the efficiency of, or prevent resistance to, cancer therapy."
For more information on this research see: Caloric restriction modulates Mcl-1 expression and sensitizes lymphomas to BH3 mimetic in mice. Blood, 2013;122(14):2402-2411. Blood can be contacted at: Amer Soc Hematology, 2021 L St NW, Suite 900, Washington, DC 20036, USA. (American Society of Hematology - www.hematology.org/; Blood - bloodjournal.hematologylibrary.org/)
Our news journalists report that additional information may be obtained by contacting O. Meynet, Netherlands Canc Inst, Amsterdam, Netherlands. Additional authors for this research include B. Zunino, L. Happo, L.A. Pradelli, J. Chiche, M.A. Jacquin, L. Mondragon, J.F. Tanti, B. Taillan, G. Garnier, J. Reverso-Meinietti, N. Mounier, J.F. Michiels, E.M. Michalak, M. Carles, C.L. Scott and J.E. Ricci (see also Lymphoproliferative Disorders).
Keywords for this news article include: Europe, Therapy, Lymphoma, Oncology, Amsterdam, Hematology, Netherlands, Lymphatic Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
To see more of the NewsRx.com, or to subscribe, go to http://www.newsrx.com .